⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL3694132 | 0.91 | NSD2 (0.38) | — | |
| SCHEMBL8781459 | 0.77 | CA1 (0.30) | — | |
| SCHEMBL27638318 | 0.75 | — | — | |
| SCHEMBL22487225 | 0.73 | — | — | |
| SCHEMBL246883 | 0.72 | — | — | |
| SCHEMBL10486710 | 0.72 | MAPT (0.34) | — | |
| SCHEMBL6509387 | 0.71 | PARG (0.36) | — | |
| SCHEMBL26553249 | 0.71 | CYP2D6 (0.32) | — | |
| SCHEMBL10542968 | 0.69 | CA2 (0.32) | — | |
| SCHEMBL1723817 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366729-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | Arcadia Medicine, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4346788-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | Arcadia Medicine, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024040497-A1 | ANTIVIRAL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 清华大学 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-112321451-B | Method for preparing cinacalcet hydrochloride drug intermediate | 福建海西新药创制有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114072390-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-5064825-A | Hypotensive agents; treatment of congestive heart failure | MERCK & CO., INC. (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0419048-A2 | Substituted pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| CN-1048546-A | Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine | MERCK & CO INC (US) | 1991-01-16 | — | — | CN | disclosed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0401030-A2 | Angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4044151-A | Sulfamidophenethanolamine therapeutic process | MEAD JOHNSON & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-3891703-A | Sulfamide process | MEAD JOHNSON & CO | 1975-06-24 | — | — | US | disclosed |